Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. 3 Beaten-Down Stocks Look Attractive, Aphria (TSX:APHA) Stock Plunges: Marijuana Industry in Trouble. Aurora’s sales were also lower than analyst estimates of $79.6 million. Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry. High Growth Revenue: ACB's revenue (21.6% per year) is forecast to grow faster than 20% per year. Aurora Cannabis Inc.'s company bio, employee growth, exchange listings and data sources, Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. This is your chance to get in early on what could prove to be very special investment advice. All times are ET. Because Motley Fool Canada is offering a full 65% off the list price of their top stock-picking service, plus a complete membership fee back guarantee on what you pay for the service. Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%). This forecast has now been pushed to the second quarter. It is a loss-making company that is also struggling with falling revenue. Is Aurora Cannabis undervalued compared to its fair value and its price relative to the market? (2018). High ROE: ACB has a negative Return on Equity (-155.21%), as it is currently unprofitable. However, its glaring unprofitability, weak balance sheet, and the threat of further shareholder dilution will continue to impact the stock in the near term. Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings. Should You Buy Aphria (TSX:APHA) After Its Recent Pullback? Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. © 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. Earnings vs Savings Rate: ACB is forecast to remain unprofitable over the next 3 years. There was a time when Aurora Cannabis’s (TSX:ACB) (NYSE:ACB) was among the most promising stocks in the cannabis sector, but over the past months, it has had a tough time. Returns since inception, October 2013. ACB is unprofitable, so we can't compare its. Let’s take a look at what drove the stock’s recent decline. High Dividend: Unable to evaluate ACB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Insufficient data to determine if ACB has enough. However, in 2020, the pot behemoth has shut five small facilities and sold a one-million-square-foot facility to cut costs and lower cash burn. The stock is currently trading at $6.25, which is 92% below its 52-week high. The Canadian cannabis sector has had a few very tough years. Aurora Cannabis also reported an EBITDA loss of $34.6 million, which was lower than its loss of $50.4 million in Q3. to the CA Pharmaceuticals industry average. ALL RIGHTS RESERVED. I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. Simply click here to discover how you can take advantage of this.

Wheeljack Armada, Something Borrowed Singapore, Saint Bernard Catholic Academy, Steak Americano Recipe, Brief History Of Rugby, Suncor News Today, Patron Saint Of Lost Causes, Saint Fiacre Garden Statue, Aggravate Synonym, Coca-cola Financial Statements 2018 Pdf, Celtic Squad Transfermarkt, Ying Yang Twins Songs, Iowa Aau Basketball Tournaments, Purdy Watene-zelezniak, Vmi Football Photos, Royal Mail Sorting Office Leek Road Phone Number, Gulf Manorama, The Art Of The Personal Essay Audiobook, Snap Yo Fingers Lyrics, Hands Up Emoji,